Advancing Mitochondrial Therapeutics: Synthesis and Pharmacological Evaluation of Pyrazole-Based Inhibitors Targeting the Mitochondrial Pyruvate Carrier

The study investigates pyrazole-based inhibitors targeting the mitochondrial pyruvate carrier (MPC), which is linked to diseases such as metabolic disorders, cancer, and hair loss. Several new compounds were identified, with BE1985 showing promising drug-like properties despite being less potent than UK-5099. The research highlighted the importance of certain substitutions, like trifluoromethyl and halogens, in enhancing inhibitory potency. Compounds such as BE2639, BE2704, and BE2647 demonstrated strong potential with sub-micromolar EC50 values. The study also found that these inhibitors do not activate PPARγ, avoiding side effects of thiazolidinediones, and showed promise in reducing hepatic stellate cell activation, indicating potential for treating metabolic dysfunction-associated steatohepatitis (MASH). Future research will focus on in vivo pharmacokinetic studies and evaluations in mouse models.